(Q43269846)

17 November 2017

title

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients (English)

1 reference

17 November 2017

0 references

1 reference

1 reference

11

Stefan Zeuzem

1 reference

17 November 2017

Simone Susser

1

1 reference

17 November 2017

Christoph Welsch

2

1 reference

17 November 2017

Yalan Wang

3

1 reference

17 November 2017

Markus Zettler

4

1 reference

17 November 2017

Francisco S Domingues

5

1 reference

17 November 2017

Ursula Karey

6

1 reference

17 November 2017

Eric Hughes

7

1 reference

17 November 2017

Robert Ralston

8

1 reference

17 November 2017

Xiao Tong

9

1 reference

17 November 2017

Eva Herrmann

10

1 reference

17 November 2017

Christoph Sarrazin

12

1 reference

17 November 2017

language of work or name

English

0 references

publication date

1 December 2009

1 reference

17 November 2017

1 reference

17 November 2017

volume

50

1 reference

17 November 2017

issue

6

1 reference

17 November 2017

page(s)

1709-1718

1 reference

Evidence of Recombination in Intrapatient Populations of Hepatitis C Virus

17 November 2017

cites work

1 reference

Diagnosis, management, and treatment of hepatitis C

21 January 2018

1 reference

Treatment of chronic hepatitis C infection with peginterferons plus ribavirin

21 January 2018

1 reference

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

21 January 2018

1 reference

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

21 January 2018

1 reference

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

21 January 2018

1 reference

Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)

21 January 2018

1 reference

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.

21 January 2018

1 reference

Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro

21 January 2018

1 reference

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

21 January 2018

1 reference

Characterization of resistance mutations against HCV ketoamide protease inhibitors

21 January 2018

1 reference

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

21 January 2018

1 reference

Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus

21 January 2018

1 reference

Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease

21 January 2018

1 reference

A continuous spectrophotometric assay for the hepatitis C virus serine protease

21 January 2018

1 reference

Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations

21 January 2018

1 reference

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

21 January 2018

1 reference

Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations

21 January 2018

1 reference

Replication of the hepatitis C virus

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/HEP.23192

1 reference

17 November 2017

1 reference